Literature DB >> 3943921

Comparison of doxorubicin-induced DNA damage in doxorubicin-sensitive and -resistant P388 murine leukemia cells.

G Capranico, T Dasdia, F Zunino.   

Abstract

Doxorubicin-induced DNA damage was studied in the P388 leukemia cell line and in a doxorubicin-resistant subline by alkaline elution techniques. DNA single-strand breaks and DNA-protein cross-links were determined. Whereas, in the sensitive line, 1 hr exposure to drug induced DNA damage in a concentration-dependent manner, in the resistant line only a marginal effect was observed at high drug concentrations. In contrast, elution kinetics of DNAs from cells irradiated with X-rays were similar in both lines. Although a reduced intracellular drug accumulation was found in resistant cells, this difference could not account for the marked reduction in doxorubicin-induced DNA damage. The degree of resistance of the P388 subline was reduced about 7-fold by verapamil, whereas the extent of DNA damage was unaffected. These results suggest the presence of alternative modes of resistance, independent of membrane changes, in highly resistant cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943921     DOI: 10.1002/ijc.2910370210

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Lack of cross-resistance of a doxorubicin-resistant B16 melanoma line with 4'-deoxy-4'-iodo-doxorubicin.

Authors:  R Supino; M Mariani; E Prosperi; G Parmiani
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Differential cytotoxicity of combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines.

Authors:  A T McGown; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance.

Authors:  D W Roberts; P D Foglesong; E Parganas; L Wiggins
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

Authors:  B Schott; D Londos-Gagliardi; C Ries; S Huet; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Antitumor activity of new anthracycline analogues in combination with interferon alfa.

Authors:  M E Berens; T Saito; C E Welander; E J Modest
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

6.  Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

Authors:  B Y Bugg; M K Danks; W T Beck; D P Suttle
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

7.  Activity of the pyrazoloacridines against multidrug-resistant tumor cells.

Authors:  J Sebolt; M Havlick; K Hamelehle; J Nelson; W Leopold; R Jackson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Doxorubicin cellular pharmacokinetics and DNA breakage in a multi-drug resistant B16 melanoma cell line.

Authors:  R Supino; M Mariani; G Capranico; A Colombo; G Parmiani
Journal:  Br J Cancer       Date:  1988-02       Impact factor: 7.640

9.  P-glycoprotein gene amplification and expression in multidrug-resistant murine P388 and B16 cell lines.

Authors:  G Capranico; P De Isabella; C Castelli; R Supino; G Parmiani; F Zunino
Journal:  Br J Cancer       Date:  1989-05       Impact factor: 7.640

10.  Flow cytometric analysis of Hoechst 33342 uptake as an indicator of multi-drug resistance in human lung cancer.

Authors:  S A Morgan; J V Watson; P R Twentyman; P J Smith
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.